V
0.478
-0.03 (-5.31%)
| Previous Close | 0.505 |
| Open | 0.560 |
| Volume | 61,565,556 |
| Avg. Volume (3M) | 2,271,288 |
| Market Cap | 1,670,515 |
| Price / Sales | 9.98 |
| Price / Book | 0.540 |
| 52 Weeks Range |
| Operating Margin (TTM) | -6,184.31% |
| Diluted EPS (TTM) | -1.70 |
| Quarterly Revenue Growth (YOY) | 75.90% |
| Total Debt/Equity (MRQ) | 8.98% |
| Current Ratio (MRQ) | 3.25 |
| Operating Cash Flow (TTM) | -9.46 M |
| Levered Free Cash Flow (TTM) | -5.03 M |
| Return on Assets (TTM) | -75.10% |
| Return on Equity (TTM) | -35.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | VivoSim Labs, Inc. | - | - |
AIStockmoo Score
0.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.00% |
| % Held by Institutions | 6.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Albion Financial Group /Ut | 31 Mar 2026 | 159 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |